戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tologous CD4 T cells and was attributed to a transfusion reaction.
2      Twenty-two (1.1%) had delayed serologic transfusion reaction.
3 n TRALI or control PCs that did not elicit a transfusion reaction.
4 lood itself, or the probability or extent of transfusion reaction.
5 for a clinically significant acute hemolytic transfusion reaction.
6 can cause life-threatening delayed hemolytic transfusion reactions.
7 ating a risk for Vel blood typing errors and transfusion reactions.
8 t time of transfusion and review of reported transfusion reactions.
9 ll as the signs, symptoms, and management of transfusion reactions.
10 eic plasma carries with it risks for adverse transfusion reactions.
11 sociated with laboratory evidence of delayed transfusion reactions.
12 lung injury, and acute and delayed hemolytic transfusion reactions.
13 ibodies to HNA-2a frequently cause pulmonary transfusion reactions.
14 177, and the role of antibodies to HNA-2a in transfusion reactions.
15 blood components frequently causes pulmonary transfusion reactions.
16 pansion as well as the risk of infection and transfusion reactions.
17 es in some adverse events, such as hemolytic transfusion reactions.
18 smission, and recurrent febrile nonhemolytic transfusion reactions.
19 that could lead to immune mediated hemolytic transfusion reactions.
20 ew opportunistic event/death or frequency of transfusion reactions.
21 peutic approaches for these life-threatening transfusion reactions.
22 e antigenic determinants, thereby minimizing transfusion reactions.
23  the most frequently implicated component in transfusion reactions.
24 in platelet concentrates that caused adverse transfusion reactions.
25 ction transmission, alloimmunization, and/or transfusion reactions.
26                               A total of 284 transfusion reactions (0.55%) were reported by passive s
27 tious reactions include febrile nonhemolytic transfusion reactions, allergic transfusion reactions, t
28  prophylactic use and treatment of hemolytic transfusion reactions and complement-mediated hemolytic
29 including life-threatening delayed hemolytic transfusion reactions and difficulty in finding compatib
30 nically significant problem that can lead to transfusion reactions and difficulty in locating future
31 te red blood cell (RBC) destruction, causing transfusion reactions and hemolytic anemia.
32 at block antibody binding in the settings of transfusion reactions and hemolytic disease of the newbo
33  against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability of compatib
34 usion requirements, the incidence of delayed transfusion reactions, and de novo abs after transplant
35  for the specific management of anaphylactic transfusion reactions are contradictory as to the utilit
36                                              Transfusion reactions are often mediated by cytokines in
37  solution, designed to reduce plasma-related transfusion reactions, are also increasingly available b
38 fusion, particularly hepatitis and hemolytic transfusion reactions, became increasingly evident.
39  alloantibodies, including delayed hemolytic transfusion reactions (DHTRs) and identifying compatible
40 rophage infusion were well tolerated with no transfusion reactions, dose-limiting toxicities or macro
41 p erythrocytes may pose a risk for hemolytic transfusion reactions due to their elevated PX2 levels.
42                                    Hemolytic transfusion reactions (HTRs) are potentially fatal compl
43                                    Hemolytic transfusion reactions (HTRs) can produce serious and pot
44                                    Hemolytic transfusion reactions (HTRs) due to incompatible red blo
45 he pathophysiology of IgG-mediated hemolytic transfusion reactions (HTRs), and deeper understanding i
46 related acute lung injury (TRALI), hemolytic transfusion reactions (HTRs), and transfusion-associated
47 echanisms that can trigger delayed hemolytic transfusion reactions in sickle cell disease, and we des
48 ere was a greater than expected frequency of transfusion reactions in the CP group (2.8% reaction rat
49 cidence of allergic and nonhemolytic febrile transfusion reactions in two large studies.
50             Thus, understanding of hemolytic transfusion reactions is generated through clinical case
51                               Some hemolytic transfusion reactions may have serious sequelae includin
52 nditions such as sickle cell anemia, sepsis, transfusion reactions, medical-device associated hemolys
53 te lung injury (n = 11), and severe allergic transfusion reactions (n = 3).
54 patient care events (n=66, 11.2%), and blood transfusion reactions (n=3, 0.5%).
55 he probability of life-threatening hemolytic transfusion reactions, not all patients generate anti-RB
56                                              Transfusion reactions occurred in 2 (0.4) placebo recipi
57 atologic entities, such as delayed hemolytic transfusion reaction or immune thrombocytopenia, might a
58                                           No transfusion reactions or any serious adverse event was r
59 ally resulting in acute or delayed hemolytic transfusion reactions or in difficulty locating compatib
60 support; length of stay in the hospital; and transfusion reactions) or in the subgroup analyses.
61  the impact on infectious complications, (2) transfusion reaction rate, (3) leukodepletion, (4) reduc
62 lood induce antibody responses and hemolytic transfusion reactions similar to those seen in patients.
63                                       Septic transfusion reactions (STRs) resulting from transfusion
64 ctoriness to transfusions, alloimmunization, transfusion reactions, the transmission of infectious ag
65 nonhemolytic transfusion reactions, allergic transfusion reactions, transfusion-associated circulator
66 ion of incompatible blood, acute and delayed transfusion reactions, transfusion-related acute lung in
67 ile neutropenia, salmonella gastroenteritis, transfusion reaction, trigeminal nerve disorder, and uri
68 rome (ARDS; four [4%] vs two [4%]), allergic transfusion reactions (two [2%] vs two [4%]), and respir
69 nd management of each diagnostic category of transfusion reaction using evidence-based recommendation
70            These mainly include allergic and transfusion reactions, volume overload, antibody formati
71                                              Transfusion reactions were fewer following PCT platelets
72                   Antibody-induced hemolytic transfusion reactions were first described over 300 year
73                Any adverse events (excluding transfusion reactions) were reported for 39 (8.2%) place
74 verload is the most frequent serious adverse transfusion reaction, with an incidence close to 1% of t